|
1
|
Boll D, Karim-Kos HE, Verhoeven RH, et al:
Increased incidence and improved survival in endometrioid
endometrial cancer diagnosed since 1989 in The Netherlands: a
population based study. Eur J Obstet Gynecol Reprod Biol.
166:209–214. 2013. View Article : Google Scholar
|
|
2
|
Gadducci A, Cosio S and Genazzani AR: Old
and new perspectives in the pharmacological treatment of advanced
or recurrent endometrial cancer: hormonal therapy, chemotherapy and
molecularly targeted therapies. Crit Rev Oncol Hematol. 58:242–256.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tavares V, Hirata MH and Hirata RD:
Peroxisome proliferator-activated receptor γ (PPAR γ): molecular
study in glucose homeostasis, lipid metabolism and therapeutic
approach. Arq Bras Endocrinol Metabol. 51:526–533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berstein LM, Kvatchevskaya JO, Poroshina
TE, Kovalenko IG, et al: Insulin resistance, its consequences for
the clinical course of the disease, and possibilities of correction
in endometrial cancer. J Cancer Res Clin Oncol. 130:687–693. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsukahara T and Haniu H: Peroxisome
proliferator-activated receptor gamma overexpression suppresses
proliferation of human colon cancer cells. Biochem Biophys Res
Commun. 424:524–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reka AK, Goswami MT, Krishnapuram R,
Standiford TJ and Keshamouni VG: Molecular cross-regulation between
PPAR-γ and other signaling pathways: implications for lung cancer
therapy. Lung Cancer. 72:154–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang Y, Huang Y, Cheng C, et al:
Combination of thiazolidinedione and hydralazine suppresses
proliferation and induces apoptosis by PPARγ up-expression in
MDA-MB-231 cells. Exp Mol Pathol. 91:768–774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ito K, Utsunomiya H, Niikura H, Yaegashi N
and Sasano H: Inhibition of estrogen actions in human gynecological
malignancies: new aspects of endocrine therapy for endometrial
cancer and ovarian cancer. Mol Cell Endocrinol. 340:161–167. 2011.
View Article : Google Scholar
|
|
9
|
Shabani N, Kuhn C, Kunze S, et al:
Prognostic significance of oestrogen receptor alpha (ERα) and beta
(ERβ), progesterone receptor A (PR-A) and B (PR-B) in endometrial
carcinomas. Eur J Cancer. 43:2434–2444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ito K, Utsunomiya H, Yaegashi N and Sasano
H: Biological roles of estrogen and progesterone in human
endometrial carcinoma - new developments in potential endocrine
therapy for endometrial cancer. Endocr J. 54:667–679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pearce ST and Jordan VC: The biological
role of estrogen receptors α and β in cancer. Crit Rev Oncol
Hematol. 50:3–22. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kurebayashi J, Otsuki T, Kunisue H, Tanaka
K, Yamamoto S and Sonoo H: Expression levels of estrogen
receptor-α, estrogen receptor-β, coactivators, and corepressors in
breast cancer. Clin Cancer Res. 6:512–518. 2000.PubMed/NCBI
|
|
13
|
Mann S, Laucirica R, Carlson N, et al:
Estrogen receptor beta expression in invasive breast cancer. Hum
Pathol. 32:113–118. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin CY, Ström A, Li Kong S, et al:
Inhibitory effects of estrogen receptor beta on specific
hormone-responsive gene expression and association with disease
outcome in primary breast cancer. Breast Cancer Res. 9:R252007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jensen EV and Jordan VC: The estrogen
receptor: a model for molecular medicine. Clin Cancer Res.
9:1980–1989. 2003.PubMed/NCBI
|
|
16
|
Yuan H, Kopelovich L, Yin Y, Lu J and
Glazer RI: Drug-targeted inhibition of peroxisome
proliferator-activated receptor-gamma enhances the chemopreventive
effect of anti-estrogen therapy. Oncotarget. 3:345–356.
2012.PubMed/NCBI
|
|
17
|
Tateishi Y, Kawabe Y, Chiba T, et al:
Ligand-dependent switching of ubiquitin-proteasome pathways for
estrogen receptor. EMBO J. 23:4813–4823. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kato S: Estrogen receptor-mediated
cross-talk with growth factor signaling pathways. Breast Cancer.
8:3–9. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Z, Zhou D, Lai Y, et al: Estrogen
induces endometrial cancer cell proliferation and invasion by
regulating the fat mass and obesity-associated gene via PI3K/AKT
and MAPK signaling pathways. Cancer Lett. 319:89–97. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Glass CK, Holloway JM, Devary OV and
Rosenfeld MG: The thyroid hormone receptor binds with opposite
transcriptional effects to a common sequence motif in thyroid
hormone and estrogen response elements. Cell. 54:313–323. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X and Kilgore MW: Signal cross-talk
between estrogen receptor alpha and beta and the peroxisome
proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7
breast cancer cells. Mol Cell Endocrinol. 194:123–133. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nickkho-Amiry M, McVey R and Holland C:
Peroxisome proliferator-activated receptors modulate proliferation
and angiogenesis in human endometrial carcinoma. Mol Cancer Res.
10:441–453. 2012. View Article : Google Scholar
|
|
23
|
Mansure JJ, Nassim R and Kassouf W:
Peroxisome proliferator-activated receptor γ in bladder cancer: a
promising therapeutic target. Cancer Biol Ther. 8:6–15. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ota K, Ito K, Suzuki T, et al: Peroxisome
proliferator-activated receptor γ and growth inhibition by its
ligands in uterine endometrial carcinoma. Clin Cancer Res.
12:4200–4208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brody F, Hill S, Celenski S, et al:
Expression of ectonucleotide pyrophosphate phosphodiesterase and
peroxisome proliferator activated receptor γ in morbidly obese
patients. Surg Endosc. 21:941–944. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Houston KD, Copland JA, Broaddus RR,
Gottardis MM, Fischer SM and Walker CL: Inhibition of proliferation
and estrogen receptor signaling by peroxisome
proliferator-activated receptor γ ligands in uterine leiomyoma.
Cancer Res. 63:1221–1227. 2003.PubMed/NCBI
|
|
27
|
Keller H, Givel F, Perroud M and Wahli W:
Signaling cross-talk between peroxisome proliferator-activated
receptor/retinoid X receptor and estrogen receptor through estrogen
response elements. Mol Endocrinol. 9:794–804. 1995.PubMed/NCBI
|
|
28
|
Kliewer SA, Umesono K, Noonan DJ, Heyman
RA and Evans RM: Convergence of 9-cis retinoic acid and peroxisome
proliferator signalling pathways through heterodimer formation of
their receptors. Nature. 358:771–774. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Knapp P, Chabowski A, Blachnio-Zabielska
A, Jarzabek K and Wołczyński S: Altered peroxisome-proliferator
activated receptors expression in human endometrial cancer. PPAR
Res. 2012:4715242012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Issemann I and Green S: Activation of a
member of the steroid hormone receptor superfamily by peroxisome
proliferators. Nature. 347:645–650. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saegusa M and Okayasu I: Changes in
expression of estrogen receptors alpha and beta in relation to
progesterone receptor and pS2 status in normal and malignant
endometrium. Jpn J Cancer Res. 91:510–518. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chakravarty D, Srinivasan R, Ghosh S,
Rajwanshi A and Gopalan S: Estrogen receptor beta (ERbeta) in
endometrial simple hyperplasia and endometrioid carcinoma. Appl
Immunohistochem Mol Morphol. 16:535–542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang Y, Zou L, Zhang C, et al: PPARγ and
Wnt/β-catenin pathway in human breast cancer: expression pattern,
molecular interaction and clinical/prognostic correlations. J
Cancer Res Clin Oncol. 135:1551–1559. 2009. View Article : Google Scholar : PubMed/NCBI
|
